3SBio (TRSBF) Debt-to-Equity : 0.35 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is 3SBio Debt-to-Equity?

3SBio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $297 Mil. 3SBio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $380 Mil. 3SBio's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $1,965 Mil. 3SBio's debt to equity for the quarter that ended in Dec. 2023 was 0.34.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for 3SBio's Debt-to-Equity or its related term are showing as below:

TRSBF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07 Med: 0.35 Max: 0.66
Current: 0.35

During the past 10 years, the highest Debt-to-Equity Ratio of 3SBio was 0.66. The lowest was 0.07. And the median was 0.35.

TRSBF's Debt-to-Equity is ranked worse than
68.32% of 1070 companies
in the Biotechnology industry
Industry Median: 0.14 vs TRSBF: 0.35

3SBio Debt-to-Equity Historical Data

The historical data trend for 3SBio's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3SBio Debt-to-Equity Chart

3SBio Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.29

0.27

0.22

0.35

3SBio Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.22	0.32	0.35	0.37	0.35

Competitive Comparison of 3SBio's Debt-to-Equity

For the Biotechnology subindustry, 3SBio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

3SBio's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3SBio's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where 3SBio's Debt-to-Equity falls into.

3SBio Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

3SBio's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(297.098	+	380.452)	/	1965.459
	=	0.34

3SBio's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(297.098	+	380.452)	/	1965.459
	=	0.34

3SBio (OTCPK:TRSBF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

3SBio Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of 3SBio's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

3SBio (TRSBF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio Inc (OTCPK:TRSBF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

01530:Hong Kong 83B:Germany

Address

No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN, 110027

Website

https://www.3sbio.com

3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.

3SBio (TRSBF) Headlines

No Headlines